Effects of Nutraceuticals and Botanicals on Macrophage Cholesterol Efflux: Implications for Atherosclerosis

Grace Megumi Sotherden, Harumi Uto-Kondo, Makoto Ayaori and Katsunori Ikewaki*

Division of Anti-Aging and Vascular Medicine, National Defense Medical College, Tokorozawa, Japan

Abstract: To date, the literature on high-density lipoprotein (HDL) levels as an inverse risk factor for atherosclerosis has mainly been observational, and it is likely that the metabolism and function of HDL is a more significant determinant of cardiovascular disease. As an example, as cholesterol is effluxed out of macrophages and carried to the liver via HDL for excretion, reduced cholesterol efflux can result in increased cholesterol accumulation. In terms of atherosclerosis risk, increasing cholesterol efflux is theoretically a strategy that can be considered as the groundwork of cardiovascular disease treatment and prevention. However, until now, there has not been a pharmaceutical agent that has effectively increased reverse cholesterol transport (RCT) at all steps of the process. Here is a review of the research on natural compounds present in edible foods and their observed in vitro and in vivo (and even ex vivo) effects on the first step of RCT: macrophage cholesterol efflux. The findings here are preliminary and contradictory, making it hard to translate the evidence on most of these naturally occurring agents into clinical applications.

Keywords: Nutrition, reverse cholesterol transport, HDL, CVD, lipoproteins.

1. INTRODUCTION

The Adult Treatment Panel III (ATPIII) cholesterol guidelines set LDL-cholesterol(C) as a primary target and first recommends therapeutic lifestyle change (TLC), followed by drug therapy where HMG-CoA reductase inhibitors (statins) are mainly used to lower LDL-C. A recent meta-analysis demonstrates that lowering LDL-C by statins reduces cardiovascular morbidity by about 30% [1]. At the same time, this fact also implies that there remains as much as 70% of risk which is independent of LDL-C lowering. Among the residual risk, high density lipoprotein (HDL) may play a pivotal role in reducing the risk since HDL exerts cardioprotective functions by promoting reverse cholesterol transport (RCT) via, for example, upregulation of key transporters, and thus efflux of cholesterol from macrophages lining arterial walls.

Macrophage cholesterol efflux to HDL is the first, and very critical, step in RCT from the periphery to the liver for excretion into bile or feces. Cholesterol efflux, in theory, decreases the likelihood of potentially deadly atheroma development in arteries. Impaired HDL-mediated cholesterol efflux, on the other hand, is one of the factors that leads to cholesterol accumulation in macrophages. Therefore, increasing cholesterol efflux may be an effective strategy for atherosclerosis prevention and treatment.

Upregulation of the ATP-binding cassette subfamilies (ABCA1 and ABCG1) and the scavenger receptor class B1, type B (SR-B1), the most valuable players in RCT, have been shown to increase cholesterol efflux out of the macrophages that cluster in the arterial lining. SR-B1 also mediates the selective uptake of cholesteryl esters to the hepatocytes, resulting in promoted RCT. Yet another player connected to cholesterol efflux is the lipogenic stearoyl CoA desaturase (SCD1) enzyme, which converts saturated fatty acids, i.e. palmitic acid, to monounsaturated fatty acids (MUFAs), i.e. palmitoleic acid. MUFAs tend to, more so than other fatty acids, be taken up into triacylglycerols and cholesteryl esters. In addition, PON1 and PON2 of the paraoxonases family have been found to be involved in protection against cholesterol-rich foam cell synthesis and atherogenesis. PON1 has been shown to be involved in HDL-mediated cholesterol efflux from macrophages. And finally, expression of ABCA1 and ABCG1 in macrophages is mediated by the nuclear receptor liver X receptors (LXR), which partner with retinoid X receptors (RXR) as heterodimers. Further, peroxisome proliferator-activated receptors (PPAR) are thought to be involved in ABCA1 expression upregulation.

Research in natural compounds have explored the concept of raising HDL-C, yet have yielded mixed results. For example, eicosapentaenoic acid (EPA) has been shown to increase HDL-C yet has decreased macrophage cholesterol efflux in vitro [2, 3]. Rader et al. demonstrated the complicated nature of HDL with regard to metabolism and anti-atherosclerotic properties and proposed that the efflux hypothesis, instead of the HDL-C hypothesis, would relate to the cardioprotective properties attributed to HDL [4].

*Address corresponding to this author at the Division of Anti-Aging and Vascular Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan; Tel: 81-4-2905-1211, ext. 2576, 2372; Fax: 81-4-2996-5202; E-mail: katsunoriike@ndmc.ac.jp
The following paper is a comprehensive review of the existing literature on nutritional therapeutics and their effects on cholesterol efflux. A number of studies illuminate the usages of nutritional therapeutics for dyslipidemia and atherosclerosis, but some of the identified studies have not looked into the molecular mechanisms behind their anti-atherosclerotic properties with regard to cholesterol efflux. We narrowed the review to studies that found an effect of the intervention specifically at this first step of RCT, namely cholesterol efflux. To date there has not been, to the knowledge of the authors, a comprehensive review of the literature on nutraceuticals and macrophage cholesterol efflux.

The following terms (or combination of terms) were searched on PUBMED databases: atherosclerosis, fruits, vegetables, plants, botanicals, nutraceuticals, macrophage efflux, cholesterol efflux, food, nutrition, cholesterol flux, HDL metabolism, RCT, fatty acids, and food factors. All studies pertaining to cells other than macrophages were excluded. Studies that could not be found in full on PUBMED were excluded from the review.

2. POLYPHENOLS, ANTIOXIDANTS AND OTHER NATURAL COMPOUNDS

Resveratrol is a polyphenol found in red wine, berries, etc. Sevov et al. found that resveratrol increased LXRα mRNA expression in both THP-1 derived macrophages and human macrophages [5]. LXRα regulates the expression of ABCA1, ABCG1, and apoE, which are key players in cholesterol efflux. Resveratrol caused apoE mRNA expression to increase threefold and ABCA1 mRNA expression to double in THP-1 macrophages, and ABCA1 and ABCG1 mRNA expression to increase in human macrophages. Berrougui, et al. found that resveratrol dose-dependently increased apoA-1-mediated cholesterol efflux. Based on the premise that oxidative damage to cells impairs cholesterol efflux, the authors induced oxidative stress on macrophages, and subsequently observed impaired HDL3-mediated cholesterol efflux, but resveratrol dose-dependently restored cholesterol efflux from these macrophages [6]. Voloshyna et al. found that resveratrol upregulated ABCA1, ABCG1, SR-BI and also 27-hydroxylase (which is involved in the excretion of intracellular cholesterol). At the same time, resveratrol suppressed foam cell formation in cholesterol-loaded macrophages [7].

In a recent study, curcumin, a component of the spice turmeric (Curcuma longa) was found to upregulate ABCA1 expression, whereby increasing apoA-1-mediated cholesterol efflux from macrophages, with significant increases at 20 and 40 μM compared to the control [8].

In a study by Xie et al., seven phenolic metabolites were identified from blueberry consumption: hippuric acid, 3-hydroxyphenylacetic acid, 3-hydroxybenzoic acid, ferulic acid, 3-(3-hydroxyphenyl) propionic acid, 3-(4-hydroxyphenyl)propionic acid, and 3-hydroxycinnamic acid [9]. The administration of these seven phenolic acids to Raw 264.7 macrophages in a separate study by the same authors, as compared to control macrophages, significantly increased (threefold) both the expression and protein levels of ABCA1 (P<0.05) [10].

Ingested anthocyanins are metabolized to various aromatic and phenolic compounds, such as the gut microbiotic metabolite protocatechuic acid (PCA).
derived from cyanidin-3-O-β-glucoside (Cy-3-G), an anthocyanin pigment, and because absorption of anthocyanins has been proposed to be low, Wang et al. studied the effects of such a metabolite (PCA), previously shown to have anti-atherosclerotic properties, on RCT in apoE-knockout mice [11, 12]. The in vitro part of the study showed that PCA significantly increased macrophage cholesterol efflux to lipid-poor apo-A-1 or HDL; however, Cy-3-G was unable to show an effect on macrophage cholesterol efflux. In addition, ABCA1 and ABCG1 expression (but not SR-BI) increased in THP-1 macrophages. In mouse peritoneal macrophages (MPM) derived from mice fed PCA (5 mg/kg) for 14 days during the in vivo part of the study, increased gene and protein expression of both ABCA1 and ABCG1 could be seen, in addition to increased cholesterol efflux to apoA-1 and HDL. Previously, Xia et al. had found that loading cells with these anthocyanin metabolites decreased macrophage and macrophage-derived foam cell intracellular cholesterol concentrations [13]. To confirm that this was not because of actions on cholesterol synthesis, the authors tested the [3H] cholesterol efflux from the cells and found that it had increased 2-fold (compared to the control cells). This increase in cholesterol efflux was mediated by apoA-1. In a randomized, double-blind, placebo-controlled study of dyslipidemic human subjects given twice-daily administration of 160 mg of anthocyanin derived from berries for 12 weeks, HDL-cholesterol concentrations were found to be increased (13.7% in the anthocyanin group vs. 2.8% for placebo; P< 0.001), and cholesterol efflux had increased (by 20.0% vs. 0.2% in the placebo group; P< 0.001) [14].

Pomegranate juice’s main polyphenols are anthocyanins, gallic and ellagic acids, ellagic tannins and catechins. Ellagic acid is also found in berries and some nuts. Park et al. found that ellagic acid increased macrophage cholesterol efflux by approximately 10 and 9% at 1μmol/L and 5 μmol/L, respectively, presumably due to the increase ABCA1 mRNA expression that was observed in this study (and most likely not due to SR-BI induction in this case) [15]. In Kaplan et al., pomegranate juice was given to apoE-deficient mice exhibiting advanced atherogenesis. Pomegranate juice significantly increased macrophage cholesterol efflux (by 39%) as compared to the placebo [16]. Rosenblat et al. used macrophages from PON1- and PON2-knockout mice given pomegranate juice, and found that, compared to the control macrophages, the treated macrophages exhibited a significant 22% increase in HDL-mediated cholesterol efflux [17]. The significance of this observation is that a defect of paraoxonase incurs a susceptibility to atherosclerosis, and according to this study, pomegranate juice would be able to ameliorate some aspects of this condition.

A study by Rosenblat et al. using polyphenol-rich beverages (mostly as pomegranate and black currant juices) demonstrated that in mice consuming these for at least one week, there was a significant decrease (of 8%) in macrophage cholesterol accumulation, as compared to at baseline [18]. However, compared to at baseline, there was no significant effect on efflux of cholesterol from macrophages, indicating that some other mechanism was responsible for the decrease in cellular cholesterol content. Fuhrman et al. found that in macrophages that were incubated with pomegranate juice, no significant effect on cholesterol efflux from these cells were seen as compared to macrophages not treated with pomegranate juice [19]. However, the rate of cholesterol synthesis in the treated group macrophages was significantly decreased by 50% (P<0.01) as compared to the control macrophages.

Uto-Kondo et al. had found that coffee, which is rich in the polyphenols caffeic acid and ferulic acid, increases cholesterol efflux from macrophages. In THP-1 macrophages, both caffeic and ferulic acids significantly increased HDL-mediated cholesterol efflux by 1.4 +/- 0.2-fold (p<0.01) and 1.4 +/- 0.3-fold (p<0.01), respectively, and upregulated the gene and protein expression of ABCG1 and SR-BI, but not of ABCA1. Given that ABCA1 was not upregulated, it was not surprising that neither caffeic acid nor ferulic acid affected apoA-1-mediated cholesterol efflux. In addition, in human monocyte-derived macrophages (MDMs), caffeic acid increased HDL-mediated cholesterol efflux by 1.3 +/- 0.1-fold (p<0.01) and ferulic acid by 1.3 +/- 0.3-fold (p<0.05), with similar effects on the key transporters (as in THP-1 macrophages) and null effects on apoA-1-mediated cholesterol efflux. In an ex vivo human study, sera taken before and after coffee consumption was administered to corresponding human MDMs. In the MDMs cultured in sera derived after coffee consumption, the HDL-mediated cholesterol efflux increased by 1.4 +/- 0.6-fold (p<0.05) and ABCG1 and SR-BI protein expressions were upregulated by 1.7 +/- 0.4-fold (p<0.05) and 3.9 +/- 0.7-fold (p<0.01), respectively, as compared to MDMs in the sera derived before consumption of coffee [20].

In a clinical, crossover, placebo-controlled study using human subjects [21], postmenopausal women were given isoflavone supplements vs. placebo.
ABCA1-induced cholesterol efflux was not significantly different between the two groups. However, levels of pre-β high-density lipoprotein (a subclass of high-density lipoprotein) which is considered to have a greater efflux capacity, increased by 18% in the treatment group, while no other lipid parameters were affected.

A study on astaxanthin, a carotenoid found in salmon, lobster, crab and shrimp, showed that it upregulated ABCA1 and ABCG1 expression and apoA-1- and HDL-mediated macrophage cholesterol efflux, particularly at higher concentrations of 50 and 100 μmol/L [22].

Lycopene is a carotenoid found especially in tomatoes. Palozza et al. observed that ABCA1 protein expression increased by 2.2-fold in cells exposed to lycopene [23]. In addition, cav-1, a member of the caveolin family and associated with enhanced cholesterol efflux, was upregulated 2-fold in the treatment group. With these two findings, along with an observed intracellular cholesterol reduction, the authors deduced (without tracing of [3H] cholesterol radioactivity) that cholesterol efflux had been enhanced. Then more recently, in 2012, researchers found lycopene to time-dependently increase mRNA and protein expression of PPARγ, LXR-α, and ABCA1, as well as change cholesterol concentrations both inside and outside the cell, all suggesting an induction of cellular cholesterol efflux [24].

Hesperetin, a citrus bioflavonoid, was found to upregulate ABCA1 mRNA expression and significantly increased apoA-1-mediated cholesterol efflux from THP-1 macrophages at 5, 10, and 15 μM of hesperetin(p<0.05) [25].

Consumption of capsanthin, a primary carotenoid in paprika peppers (Capsicum annuum) resulted in a dose-dependent increase in HDL-cholesterol in rats (r=0.597; p<0.005) [26]. Compared with rats fed a basal diet, the rats fed a basal diet with purified capsanthin added exhibited a 44% increase in mean plasma HDL-C (p<0.05). In addition, both LCAT and apoA5 mRNA expressions were significantly upregulated, while apoA-1 mRNA expression was not significantly different. It is possible that capsanthin could increase cholesterol efflux.

Treatment of human THP-1 macrophages with S-allylcysteine (SAC), a compound found in garlic, at (10, 20 and 40 mM for 24 hours) resulted in a dose-dependent increase in mRNA and protein expression of ABCA1 as compared to control, suggesting that SAC too could affect cholesterol efflux [27].

α-Lipoic acid (α-LA), considered to be a free radical scavenger, increased the gene expression of ABCA1 and ABCG1 in α-LA-treated J774.A1 macrophages (significant at 25 and 50 μM; p<0.05), but did not increase the expression of SR-BI or SR-A [28]. The mechanism behind the upregulation of ABCA1 and ABCG1 was confirmed through the upregulation of LXR-α. In human THP-1 macrophages, the same effects were seen. α-LA significantly reduced lipid accumulation in cells and also significantly and dose-dependently (at 12.5, 25 and 50 μM; p<0.05) increased cholesterol efflux from macrophages (p<0.05).

Rosenblat et al. found that liposomal glutathione administration to apoE-deficient mice dose-dependently increased HDL-induced macrophage cholesterol efflux by 78% (at 50mg/kg/day) compared to the placebo-treated mice [29]. A seemingly contradictory finding was that consumption of liposomal glutathione by mice (at 50 mg/kg/day) lead to a significant decrease in HDL-C levels (by 21%) as compared to in the control mice. Although increased cholesterol efflux from macrophages does not necessarily increase plasma HDL level, this discrepancy between cholesterol efflux and HDL-C in the plasma again points to the extent of the complexity of HDL’s involvement in cholesterol homeostasis.

*Rosa roxburghii* (Chestnut Rose) was investigated by Zhang et al. using enzymatic fluorometric methods to quantify cellular cholesteryl ester (CE) accumulation in macrophages. They discovered that *rosa roxburghii* juice ameliorated the increase in CE accumulation (artificially induced by oxidized LDL) significantly at concentrations of 2 μl/ml (reduced by 55%) and nearly completely reduced this increase (by 96%) at 4 μl/ml. In the latter part of the experiment, control cells incubated with HDL had their CE mass reduced by 64%, demonstrating cholesterol efflux onto HDL, and *rosa roxburghii* juice also significantly reduced CE by 70% at 2μl/ml and by 88% at 4 μl/ml, also demonstrating cholesterol efflux mediated by *rosa roxburghii* juice [30].

Berrougui et al. looked at the effects of *Marrubium vulgare* (Horehound) extract on cholesterol efflux in human THP-1 macrophages. The extract dose-dependently increased cholesterol efflux. In J774-ABCA1-incubated macrophages, the authors did not
observe an increase in HDL-mediated cholesterol efflux, indicating that the effects of *M. vulgare* increased cholesterol efflux in an ABCA1-independent manner [31]. The authors discussed that *M. vulgare* leaves contain high amounts of phenols. Whether or not its antioxidant properties are responsible for the increased HDL-mediated cholesterol efflux is not known.

Yoon *et al.* found that the lactic acid bacteria *Lactobacillus rhamnosus* BFE5264 and *Lactobacillus plantarum* NR74 induced LXR activation, thus increasing expression of ABCA1 and ABCG1, whereby also increasing cholesterol efflux in THP-1 macrophages [32].

In an ex vivo, randomized study by Sierksma *et al.* wherein the subjects were given 250 ml of either white wine (12% alcohol) or white grape juice, the white wine groups experienced an increase in serum HDL-C levels by 5% (p=0.02), as well as increased cholesterol efflux by 3.4% (p < 0.05) [33]. The authors conclude that it is the alcoholic content of the wine that accounts for the difference in beneficial effects of the white wine over the white grape juice. However, a study considering the effects of n-3 fatty acids and chronic alcohol consumption, found that while an n-3 fatty-acid-enriched diet increased cholesterol efflux from macrophages by 79% compared to the control diet, an n-3 FA and alcohol-rich diet induced less of a beneficial effect (only of 25% compared to the control) [34]. Adding only alcohol to their diet decreased the cholesterol efflux from the macrophages by 21% (p<0.01). Similarly, the same researchers studied moderate consumption of alcohol, simulated in mice. In macrophages derived from the mice fed alcohol as compared to from the control mice, the HDL-mediated cholesterol efflux was decreased by 20% (p<0.05) [35].

Niacin, a member of the vitamin B family, is used as a pharmaceutical agent in lowering lipids and in increasing HDL-C. In adipocytes treated with niacin, apoA-I-mediated cholesterol efflux was increased [36]. In addition, ABCA1 mRNA expression in these adipocytes was dose-dependently increased with exposure to a medium with varying amounts of niacin (0-1.0 mmol/L). In addition, given that ABCA1-mediated cholesterol efflux is transcriptionally regulated by PPARγ and LXRα, an assay demonstrated that niacin dose-dependently induced both PPARγ and LXRα mRNA expression as well. Yvan-Charvet *et al.* compared niacin with anacetrapib (a cholesteryl ester transfer protein inhibitor) in a clinical trial to see which performed better in promoting HDL-mediated cholesterol efflux in macrophages [37]. Niacin, while it prompted a moderate increase in HDL-mediated cholesterol efflux (statistically significant at 25ul and 50 ul of the HDL-PEG supernatant), anacetrapib did so to a more significant degree. Clinical benefits of HDL-C raising therapy by niacin is yet to be proved.

### 3. LIPIDS

A study on phytosterols found that in THP-1 macrophages as well as in mouse peritoneal macrophages (MPMs), sitosterol had no effect on cholesterol efflux, while stigmasterol promoted efflux to apoA-1 by 25% (p<0.05) and also increased efflux to HDL, and increased expression of ABCA1 and ABCG1. Campesterol, on the other hand, modestly decreased efflux to HDL (p<0.05) and did not affect the efflux to apoA-1 [38].

Fucosterol, derived from marine algae, in doses of either 100 or 200 μM, increased cholesterol efflux in HDL-treated THP-1-derived macrophages compared to control cells (p<0.01) [39] (data not provided). The proposed mechanism is that it acts as an LXR-agonist.

Phosphatidylcholine, a major component of lecithin, was used in the form of soybean-derived phosphatidylcholine to incubate ECV304 human endothelial cells, resulting in a significant increase in cholesterol efflux (compared to controls) [40]. Lysophosphatidylcholine (LPC) dose-dependently (at 10, 20, 40, 80 μM) increased expression of PPAR-γ, LXR-α, and ABCA1 in macrophage foam cells [41]. When these foam cells were incubated with 40 μM of LPC for 12, 24 and 48 hours, they demonstrated time-dependent increases in cholesterol efflux. In apoE-deficient mice, the cholesterol efflux seen by LPC treatment was significantly lower, implicating the importance of apoE. The authors, through the usage of specific inhibitors of PPAR-γ, LXRα, and ABCA1, were able to confirm that LPC-induced cholesterol efflux from foam cells worked via a PPAR-γ-LXRα-ABCA1-dependent pathway, and was also mediated by apoE. In yet another study, in HDL taken from di-oleoyl-phosphatidylcholine-enriched serum, serum-mediated cholesterol efflux from J774 A.1 macrophages increased by 49% and HDL-mediated macrophage cholesterol efflux by 31% compared to control serum. In the *in vivo* part of the study, treatment mice were fed 0.2 ml of olive oil every two days for 3 weeks, with placebo mice fed just water. HDL-mediated macrophage cholesterol efflux increased by 93%
compared to in the placebo group. Next they extended the study to human subjects, having them consume 30 ml of olive oil per day for 2 weeks. Compared to pre-consumption of olive oil, serum-mediated macrophage efflux increased by 34% and HDL-mediated cholesterol efflux increased by 53% in the humans after olive oil consumption [42].

Extra virgin olive oil (EVOO), high in the MUFA oleic acid, and in antioxidants such as oleuropein, was looked at by Helal et al. in a human study in which the subjects consumed 25 ml/day of EVOO for 12 weeks. In THP-1 macrophages, EVOO was able to increase cholesterol efflux by 9.8% (p<0.01) [43]. EVOO increased cholesterol efflux from ABCA1-enriched J774 macrophages by 18.9% (p<0.001) as compared to macrophages not enriched with ABCA1. In Fu5AH cells, SR-BI-mediated cholesterol efflux was increased by 14.8% (p<0.001) and HDL-mediated SR-BI-related cholesterol efflux was increased by 16.4% at 12 hours compared to baseline (p<0.05). Also, in THP-1 macrophages, EVOO increased HDL-mediated cholesterol efflux by 11.9% (p<0.01) and upregulated ABCG1-induced HDL-mediated cholesterol efflux at 0 hours (11.8%) and significantly more so at 12 hours (24.6%), (p<0.001). In addition, HDL2-mediated cholesterol efflux in Fu5AH cells was increased by 24.1% at 12 hours compared to baseline (p<0.05) while in ABCA1-enriched J774 macrophages, HDL3-mediated cholesterol efflux was 15.2% higher than in control macrophages (p<0.05). In human monocyte-derived macrophages (HMDMs), cholesterol efflux was increased by 44% (p<0.001). In the HMDMs, regulation of both gene and protein expression was increased in ABCA1 (27.51%, p<0.0001; 16.08%, p<0.001, respectively) and ABCG1 (26.48%, p<0.001; 35.79%, p<0.01, respectively). However, both gene and protein expression were downregulated in SR-BI (by 30%, p<0.0001; 2.51%, p<0.05, respectively). Meanwhile, a study by Stein et al. on oleic acid, a monounsaturated fatty acid, found an inhibitory effect of macrophage cholesterol efflux to apoA-1 by oleic acid (by 27%) as compared to the control cells [44].

Extra virgin olive oil enriched with green tea polyphenols (EVOO-GTPP) was compared to extra virgin olive oil alone (EVOO) in administration to apo-E-deficient mice exhibiting atherosclerosis [45]. EVOO-GTPP contains MUFA, primarily which is oleic acid, in addition to phytosterols, polyphenols, and tocopherols. Green tea contains polyphenols called catechins, the main one being epigallocatechin gallate (EGCG). EVOO compared to placebo significantly increased HDL-mediated cholesterol efflux (p<0.01) and EVOO-GTPP, as compared to EVOO, even more drastically increased cholesterol efflux (the difference between EVOO-GTPP and EVOO being significant at p<0.05). Both had measureable effects on both apoA-1-mediated and HDL-mediated cholesterol efflux. EVOO and EVOO-GTPP increased HDL-mediated cholesterol efflux by 42% and 139%, respectively. In addition to the other parameters measured in this study (such as lesion size), the authors concluded that EVOO enriched with GTPPs can mitigate atherosclerosis in the apoE-deficient mice model.

Berrougui et al. studied the antioxidant component of argan oil, (from the seeds of Argania spinosa) particularly virgin argan oil phenolic extracts (VAO-PE), and found that incubation with 320 μg/ml VAO-PE increased cholesterol efflux from human THP-1 macrophages (p=0.0245) [46]. In addition, when the experimenters induced oxidation of HDL with copper, cholesterol efflux from the THP-1 macrophages was decreased, and then reversed time-dependently by 320 ug/ml of VAO-PE. Then in 2007, Berrougui et al. examined a methanolic extract of Argania spinosa L. pericarp (MEAP), which increased ABCA1-independent HDL-mediated cholesterol efflux in J774 macrophages [47].

One study tested various dietary fatty acids on macrophage cholesteryl ester accumulation and cholesterol efflux [48]. The diets of African green monkeys were supplemented with various fatty acids (n-3, saturated, monounsaturated, and n-6 fatty acids). THP-1 cells incubated with the isolated lipids from each of these various treatment groups initially did not yield differences in cholesterol efflux. However, after the cells underwent triglyceride removal, n-3 fatty acids significantly and time-dependently increased cholesterol efflux compared the other fatty acids. Similarly, in 1990, Pal & Davis had enriched cell lines with either n-6 PUFAs or n-3 PUFAs. N-3 PUFAs doubly increased the rate of cholesterol efflux from cells as did n-6 PUFAs [49].

However, Králova Lesná et al. conducted a study in which replacing saturated fatty acids with PUFAs did not result in significant changes in cholesterol efflux [50]. In addition, in 2007, Buonacorsa et al. did not find differences in cholesterol efflux in cells incubated in the plasma of subjects consuming diets of differing fatty acid composition (trans fatty acids vs. PUFAs vs. SFAs) [51]. However, the authors stated that it may be due to the low proportions of fatty acids ingested in the
Table 1: Shows a Summary of the Results

<table>
<thead>
<tr>
<th>Antioxidant/Food Source</th>
<th>Effect on Macr. Chol. Efflux</th>
<th>Proposed Mechanism(s)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resveratrol (grapes, red wine, berries, peanuts)</td>
<td>Positive</td>
<td>Upregulates LXRs, apoE, and ABCA1, ABCG1, SR-BI, and 27-hydroxylase mRNA expression; †apoA-1 mediated CE; suppresses foam cell formation</td>
<td>[5] [6] [7]</td>
</tr>
<tr>
<td>Curcumin (turmeric)</td>
<td>Positive</td>
<td>Upregulates ABCA1 via PPARγ- LXRα pathway</td>
<td>[8]</td>
</tr>
<tr>
<td>Anthocyanins (berries)</td>
<td>Positive</td>
<td>†expression and protein levels of ABCA1; metabolite might †CE to apoA-1 or HDL; upregulates ABCA1 and ABCG1</td>
<td>[9-14]</td>
</tr>
<tr>
<td>Ellagic Acid (pomegranate)</td>
<td>Positive</td>
<td>†cholesterol efflux, even in apoE-, PON1- and PON2-deficient mice</td>
<td>[15-17]</td>
</tr>
<tr>
<td>Ferulic Acid (Coffee)</td>
<td>Positive</td>
<td>†HDL-mediated CE via upregulation of SR-BI and ABCG1</td>
<td>[20]</td>
</tr>
<tr>
<td>Astaxanthin (crab, shrimp, lobster)</td>
<td>Positive</td>
<td>†apoA-1- and HDL-mediated macrophage cholesterol efflux via upregulation of ABCA1 and ABCG1</td>
<td>[22]</td>
</tr>
<tr>
<td>Lycopene (tomatoes)</td>
<td>Possibly positive</td>
<td>Upregulation of PPARγ, LXRs and thus ABCA1, as well as caveolin-1</td>
<td>[23, 24]</td>
</tr>
<tr>
<td>Hesperetin (citrus)</td>
<td>Positive</td>
<td>†upregulate apoA-1-mediated CE via †ABCA1 mRNA expression</td>
<td>[25]</td>
</tr>
<tr>
<td>α-Lipoic acid</td>
<td>Positive</td>
<td>†ABCA1 and ABCG1 through upregulation of LXRs</td>
<td>[28]</td>
</tr>
<tr>
<td>Glutathione</td>
<td>Positive—with a caveat (†CE, †HDL-C)</td>
<td>Not known</td>
<td>[29]</td>
</tr>
<tr>
<td>Oleic Acid (olive oil) &amp; Oleate</td>
<td>2 Positive, 1 Negative</td>
<td>Possibly mediated by ABCA1 and ABCG1</td>
<td>[43-45]</td>
</tr>
<tr>
<td>Epigallocatechin (EGCG) (green tea)</td>
<td>In a study comparing EGCG-enriched olive oil with plain olive oil, cholesterol efflux was significantly †</td>
<td>Not explained</td>
<td>[45]</td>
</tr>
<tr>
<td>Marrubium vulgare (Horehound)</td>
<td>Positive</td>
<td>Possibly via an ABCA1-independent pathway; rich with phenols</td>
<td>[31]</td>
</tr>
<tr>
<td>Lactobacilli</td>
<td>Positive</td>
<td>Upregulation of ABCA1 and ABCG1</td>
<td>[32]</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Conflicting</td>
<td>Not specified</td>
<td>[33-35]</td>
</tr>
<tr>
<td>Niacin</td>
<td>Positive</td>
<td>ApoA-1-mediated CE †, upregulation of ABCA1, PPARγ and LXRs mRNA expression</td>
<td>[36, 37]</td>
</tr>
<tr>
<td>Phytosterols/stanols</td>
<td>Stigmasterol: positive</td>
<td>Efflux to apoA-1 and HDL via upregulation of ABCA1 and ABCG1</td>
<td>[38, 39]</td>
</tr>
<tr>
<td></td>
<td>Fucosterol: positive</td>
<td>Fucosterol may act as an LXR agonist</td>
<td></td>
</tr>
</tbody>
</table>
study, and the general similar composition of fatty acids between the three diet groups that no real big differences in cholesterol efflux between the groups were observed.

Uehara et al. studied the effects of the unsaturated fatty acids EPA, linoleic acid (LA), arachidonic acid (AraA) and saturated fatty acids palmitic acid (PA) and stearic acid (SA) on cholesterol transport [2]. What they found was that unsaturated fatty acids dose-dependently suppressed ABCA1 gene expression and also reduced apoA-1-mediated cholesterol efflux in macrophages, LA exerting the strongest effects, then AraA, then EPA, then linoleic acid. PA, a saturated fatty acid, moderately suppressed ABCA1 while stearic acid moderately yet significantly increased ABCA1. Then in 2007 the same authors conducted another study in which the effects of unsaturated fatty acids and saturated fatty acids on cholesterol efflux were examined once more [3]. This time they found that ABCG1 gene expression was downregulated by these fatty acids. Meanwhile, saturated fatty acids transcriptionally upregulated promoters A and B of the ABCG1 gene. Stearic acid was found to significantly increase promoters A and B activity, while palmitic acid only did for promoter B. ABCG1 gene expression was decreased by 48.6% by EPA and 49.6% by LA. Likewise, ABCG1 protein expression was decreased by 40.5% by EPA, 45.8% by LA, and 35.6% by OA. Ku et al. incubated macrophages with 100 umol/L of PA, palmitoleic acid, oleic acid, linolenic acid or EPA. Without an LXR agonist, ABCA1 and ABCG1 mRNA expression were significantly decreased with unsaturated fatty acid incubation as compared with the control; however, in the presence of an LXR agonist, ABCA1 and ABCG1 mRNA levels went back to normal. However, when the LXR agonist was present, the ABC transporter protein expressions were reduced [52]. Wang & Oram found that incubation of macrophages with the unsaturated fatty acids olate and linoleate greatly reduced apoA-1-mediated cholesterol efflux from macrophages (i.e. by more than 50% at 20 hours of incubation) in a dose-dependent manner, by degrading ABCA1 [53]. (Linoleate did more so than olate.) Olate maximally inhibited cholesterol efflux at 16 hours, whereas linoleate reached this in only 4 hours. In addition, unsaturated fatty acids decreased membrane ABCA1. Linoleate and olate decreased ABCA1 in a dose-dependent manner. At the same time, saturated fatty acids did not have an effect on ABCA1, nor on apoA-1 binding to ABCA1. In particular, stearate, a saturated fatty acid, did not have an effect on apoA-1 binding to ABCA1. The effect of the unsaturated fatty acids on ABCA1 was not at the transcriptional level, as ABCA1 mRNA was not affected. What was discovered by the authors (and mentioned earlier in the paragraph), was that, instead ABCA1 degradation was increased by unsaturated fatty acids, and cholesterol efflux was inhibited.

Hu et al. demonstrated that EPA dose- and time-dependently downregulated ABCA1 protein expression (but not ABCA1 mRNA expression) and inhibited ABCA1-mediated cholesterol efflux particularly at the

---

<table>
<thead>
<tr>
<th>Antioxidant/Food Source</th>
<th>Effect on Macr. Chol. Efflux</th>
<th>Proposed Mechanism(s)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysophosphatidylcholine (LPC)</td>
<td>Positive</td>
<td>PPARγ- LXRα-ABCA1- and apoE-dependent pathways; possibly through PON1 activation</td>
<td>[40-42]</td>
</tr>
<tr>
<td>Argania Spinosa</td>
<td>Positive</td>
<td>ABCA1-independent</td>
<td>[46, 47]</td>
</tr>
<tr>
<td>Unsaturated Fatty Acids</td>
<td>Conflicting; differences between mono- and poly-UFAs</td>
<td>Not specified; decreased effects might be due to suppression of ABCA1 and possibly of ABCG1 as well</td>
<td>[48-50, 52, 53, 58]</td>
</tr>
<tr>
<td>Saturated Fatty Acids</td>
<td>Conflicting</td>
<td>Stearate ↑ABCA1 and ABCG1</td>
<td>[2, 3, 53]</td>
</tr>
<tr>
<td>EPA &amp; DHA</td>
<td>Negative</td>
<td>Inhibited ABCA1 and possibly LCAT; PPARγ by DHA; LXRγ by EPA and DHA</td>
<td>[3]</td>
</tr>
<tr>
<td>Linoleic Acid</td>
<td>Positive</td>
<td>apoA-1-mediated ABCA1, ABCG1 and SR-BI upregulation</td>
<td>[55, 57]</td>
</tr>
<tr>
<td>Walnut oil</td>
<td>Positive</td>
<td>FXR-mediated downregulation of SCD1</td>
<td>[56]</td>
</tr>
</tbody>
</table>

Key: CE, cholesterol efflux; ↑, increased; ↓, decreased.
highest doses of EPA used in the study (10 μM and 100μM) [54].

Kämmerer et al. observed that with 13-hydroxy linoleic acid (which is linoleic acid treated with an enzyme), apoA-1-mediated cholesterol efflux in macrophages was increased, as was the expression of ABCA1, ABCG1, and SR-BI [55].

Zhang et al. had found that, in foam cells derived from THP-1 macrophages treated with sera from human subjects fed walnut oil, this intervention significantly promoted cholesterol efflux by down regulating the expression of SCD1 [56]. The primary n-3 PUFA in walnuts is α-linolenic acid, which was found to activate the nuclear receptor farnesoid-X-receptor (FXR) which was responsible for the reduction in SCD1 activity. Zhang et al. further conducted a study specifically using α-linolenic acid itself and had confirmed that this reduction in SCD1 expression was indeed mediated by FXR. The n-3 PUFA α-linolenic acid had, in this study as well, increased cholesterol efflux in macrophage-derived foam cells via the inhibition of SCD1 [57].

4. CONCLUSION

Regarding lipids, the inconsistencies of the findings on cholesterol transport make them very hard to interpret. For example, regarding unsaturated fatty acids, Uehara et al. and Wang & Oram and Ku et al. had found an inhibitory effect of UFAs on cholesterol efflux [2, 3, 52, 53], while Kämmerer et al., Zhang et al., Helal et al. found stimulatory actions on unsaturated fatty acids of varying numbers of double bonds (mono-vs. poly) on cholesterol efflux [43, 55, 57].

As atherosclerotic disease is the basis for many morbidities, such as peripheral vascular disease, myocardial infarction, and ischemic stroke, the development of therapeutic interventions targeting atherosclerosis and its risk factors are in high demand. These are preliminary studies that describe cellular mechanisms of the effects of nutraceutical and botanical substances on HDL functionality. However, one cannot yet make inferences about how, at the studied doses, these therapeutics would act in the human body in terms of macrophage cholesterol efflux. Also, it is of value to note some contradictions in the literature. The effects of MUFAs tend to be unfavorable in that they decrease cholesterol efflux in macrophages, thus increasing the retention of intracellular cholesterol. This is inconsistent with the favorable effects that MUFAs in the diet have on lipid and lipoprotein profiles, namely reduction of LDL, in clinical trials. At the same time, there are also many conflicting results (some positive, some negative) regarding MUFAs and atherosclerosis in animal studies. This is a gap in the research that necessitates further research.

During the last decade starting with the cornerstone discovery of ABCA1, novel small molecules promoting antiatherogenic properties of HDL have yet to be identified. In this regard, the results of these in vitro and in vivo studies are indeed provocative. The current body of evidence presented here agrees with other studies on the cardioprotective, hypolipidemic, anti-oxidative and anti-inflammatory properties of these natural compounds, strengthening the argument that there may be some potential here for the usage of these natural compounds in atherosclerosis prevention and treatment. This is yet another reason to continue investigation in this field.

ABBREVIATIONS AND ACRONYMS

ABCA1 = ATP-binding cassette subfamily A member 1
ABCG1 = ATP-binding cassette subfamily G member 1
Apo = apolipoprotein
CVD = cardiovascular disease
HDL = high-density lipoprotein
LDL = low-density lipoprotein
LXR = liver X receptor
MDM = human monocyte-derived macrophages
MPM = mouse peritoneal macrophages
PON = paraoxonases
PPAR = peroxisome proliferator-activated receptor
RCT = reverse cholesterol transport
SCD = stearoyl CoA desaturase
SR-BI = scavenger receptor class B type I

REFERENCES

Effects of Nutraceuticals and Botanicals on Macrophage Cholesterol Efflux

Journal of Nutritional Therapeutics, 2012 Vol. 1, No. 2

105


sphingomyelin both in rats and in humans. Metabolism 2007; 56(7): 947-53.


